Tevogen, Inc. (TVGN)
5.905
-0.24
(-3.83%)
USD |
NASDAQ |
Nov 19, 16:00
5.905
0.00 (0.00%)
After-Hours: 20:00
Tevogen Debt to Equity Ratio : -0.9219 for Sept. 30, 2026
Debt to Equity Ratio Chart
Historical Debt to Equity Ratio Data
| Date | Value |
|---|---|
| September 30, 2026 | -0.9219 |
| June 30, 2026 | -1.062 |
| March 31, 2026 | -0.9625 |
| December 31, 2025 | -0.911 |
| September 30, 2025 | -0.9623 |
| June 30, 2025 | -0.7966 |
| March 31, 2025 | -0.6246 |
| December 31, 2024 | -0.4324 |
| September 30, 2024 | -0.4789 |
| June 30, 2024 | -0.2642 |
| March 31, 2024 | -0.3582 |
| Date | Value |
|---|---|
| December 31, 2023 | -1.010 |
| September 30, 2023 | 0.0635 |
| June 30, 2023 | 0.0618 |
| March 31, 2023 | 0.00 |
| December 31, 2022 | 0.00 |
| September 30, 2022 | 0.00 |
| June 30, 2022 | 0.00 |
| March 31, 2022 | 0.00 |
| December 31, 2021 | 0.00 |
| September 30, 2021 | 5.993 |
| June 30, 2021 | 5.949 |
Debt to Equity Ratio Definition
The debt to equity ratio measures the (Long Term Debt + Current Portion of Long Term Debt) / Total Shareholders' Equity. This metric is useful when analyzing the health of a company's balance sheet.
Debt to Equity Ratio Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Debt to Equity Ratio Benchmarks
| Oncolytics Biotech, Inc. | -0.0546 |
| Sangamo Therapeutics, Inc. | -1.020 |
| Sarepta Therapeutics, Inc. | 0.6888 |
| Anixa Biosciences, Inc. | 0.012 |
| Vicapsys Life Sciences, Inc. | -0.1759 |
Debt to Equity Ratio Related Metrics
| Total Assets (Quarterly) | 3.514M |
| Total Liabilities (Quarterly) | 14.81M |
| Shareholders Equity (Quarterly) | -11.29M |
| Current Ratio | 0.132 |
| Net Debt Paydown Yield | -0.55% |